華潤醫藥(03320.HK)旗下創新藥獲批臨牀試驗
華潤醫藥(03320.HK)公佈,旗下直屬全資創新藥研發機構中國藥研收到國家藥監局簽發關於NIP142膠囊的《藥物臨牀試驗批準通知書》,同意NIP142膠囊開展用於非小細胞肺癌(NSCLC)的臨牀試驗。
NIP142是中國藥研研發並具有全球自主知識產權的一類小分子創新藥,通過抑制EGFR或HER2 exon20ins突變體活性,阻斷下遊信號通路活化,進而達到抑制腫瘤增長的目的。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.